| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965705 | Vaccine | 2015 | 7 Pages |
Abstract
The IPV-aluminium hydroxide formulation constitutes a promising vaccine capable of generating strong Th1 immunity against infection with all three serotypes. A phase I/II clinical study was recently initiated.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Lars Vibe Andreasen, Lasse Bøllehuus Hansen, Peter Andersen, Else Marie Agger, Jes Dietrich,